| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Ryan Headache Center (Dr. Ryan), St. Louis, MO; Elkind Headache Center (Dr. Elkind), Mt. Vernon, NY; Headache Institute of Minnesota (Dr. Baker); Minneapolis, MN; MediSphere Medical Research Center (Dr. Mullican), Evansville, IN; and Glaxo Wellcome, Inc. (S. DeBussey and Dr. Asgharnejad), Research Triangle Park, NC.
Address correspondence and reprint requests to Dr. Robert Ryan, 621 South New Ballas Road, Suite 537, St. Louis, MO 63141.
Background: Sumatriptan nasal spray may be particularly useful for patients whose nausea and vomiting preclude them from using oral migraine medication or for patients who prefer not to use an injectable migraine medication. The objective of this study was to evaluate in two clinical studies the efficacy and tolerability of the intranasal form of sumatriptan in the acute treatment of a single migraine attack. International Headache Society-diagnosed adult migraineurs in two randomized, double-blind, parallel-group, multicenter studies (n = 409 and 436) used sumatriptan nasal spray 20 mg, 10 mg, or placebo (2:1:1) for the acute treatment of a single migraine attack at home. Predose and at predetermined postdose intervals, patients recorded headache severity (none, mild, moderate, severe); time to meaningful relief; clinical disability (none, mildly impaired, severely impaired, bed rest required); presence/absence of nausea, photophobia, and phonophobia; and the occurrence of adverse events. Two hours postdose in the two studies, moderate or severe baseline pain was reduced to mild or none in 62 to 63% of patients treated with sumatriptan 20 mg, 43 to 54% of patients treated with sumatriptan 10 mg, and 29 to 35% of placebo-treated patients (p < 0.05 20 mg versus placebo for both studies and 10 mg versus placebo for study 1). Onset of relief relative to placebo began as early as 15 minutes postdose(sumatriptan 20 mg, study 2). Clinical disability at 2 hours postdose was reported as mildly impaired or normal in 72 to 74% of patients treated with sumatriptan 20 mg, 56 to 68% of patients treated with sumatriptan 10 mg, and 47 to 58% of placebo-treated patients (p < 0.05 20 mg versus placebo for both studies). Similar efficacy rates were observed for nausea, photophobia, and phonophobia. The most common adverse event in the active treatment groups was disturbance of taste (bad, bitter, or unpleasant taste). Aside from this event, the pattern and incidence of adverse events did not differ among treatment groups. From these results we determined that sumatriptan nasal spray is a rapidly effective, well-tolerated migraine treatment. The 20-mg dose was effective in treating the entire migraine symptom complex, and the 10-mg dose was less consistently effective.
The studies described in this manuscript were funded by Glaxo Wellcome, Inc., Research Triangle Park, NC.
Received October 30, 1996. Accepted in final form May 13, 1997.
This article has been cited by other articles:
|
|
 |
|
  M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau Pharmacokinetics of Sumatriptan Nasal Spray in Children J. Clin. Pharmacol., April 1, 2004; 44(4): 359 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ahonen, M. L. Hamalainen, H. Rantala, and K. Hoppu Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial Neurology, March 23, 2004; 62(6): 883 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Dahlof Clinical applications of new therapeutic deliveries in migraine Neurology, October 28, 2003; 61(90084): S31 - 34. [Abstract] [Full Text]
|
|
|
|
|
|
M. L. Christensen, R. K. Mottern, J. T. Jabbour, and E. Fuseau Pharmacokinetics of Sumatriptan Nasal Spray in Adolescents J. Clin. Pharmacol., July 1, 2003; 43(7): 721 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. van Vliet, A. Bahra, V. Martin, N. Ramadan, S. K. Aurora, N. T. Mathew, M. D. Ferrari, and P. J. Goadsby Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study Neurology, February 25, 2003; 60(4): 630 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Snow, K. Weiss, E. M. Wall, C. Mottur-Pilson, and for the American Academy of Family Physicians and Pharmacologic Management of Acute Attacks of Migraine and Prevention of Migraine Headache Ann Intern Med, November 19, 2002; 137(10): 840 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Ryan Jr Patient Treatment Preferences and the 5-HT1B/1D Agonists Arch Intern Med, November 26, 2001; 161(21): 2545 - 2553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Winner, A. D. Rothner, J. Saper, R. Nett, M. Asgharnejad, A. Laurenza, R. Austin, and M. Peykamian A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents Pediatrics, November 1, 2000; 106(5): 989 - 997. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.-M. Kelly Migraine: pharmacotherapy in the emergency department Emerg. Med. J., July 1, 2000; 17(4): 241 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Schulze, J. E. Proctor, M. A. Dominick, A. E. Weiss, O. P. Flint, N. R. Srinivas, S. K. Durham, and B. E. Schilling Intranasal Toxicity of BMS-181885, A Novel 5-HT1 Agonist International Journal of Toxicology, September 1, 1999; 18(5): 285 - 296. [Abstract] [PDF]
|
|
|
|
|
|
M. A. Ueberall and D. Wenzel Intranasal sumatriptan for the acute treatment of migraine in children Neurology, April 1, 1999; 52(7): 1507 - 1507. [Abstract] [Full Text]
|
|
|
|
 |
|
 Managing migraine DTB, June 1, 1998; 36(6): 41 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J GOADSBY A triptan too far? J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
 |
|
 New Preparations for Migraine Journal Watch Emergency Medicine, February 1, 1998; 1998(201): 15 - 15. [Full Text]
|
|
|
|
 |
|
 New Drug Preparations for Migraine Journal Watch Psychiatry, February 1, 1998; 1998(201): 19 - 19. [Full Text]
|
|
|
|
 |
|
 NEW DRUG PREPARATIONS FOR MIGRAINE Journal Watch (General), December 16, 1997; 1997(1216): 4 - 4. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
